Open AccessPlasma Concentrations of Fibroblast Growth Factors 21 and 19 in Patients with Cushing's Syndrome
Author(s) -
Viktorie Ďurovcová,
Marek Jakóbisiak,
Václav Hána,
Martin Matoulek,
Vı́t Zikán,
D Haluzíková,
Petra Kaválková,
Z Lacinová,
Michal Kršek,
Martin Haluzı́k
Publication year - 2010
Publication title -
physiological research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.647
H-Index - 70
eISSN - 1802-9973
pISSN - 0862-8408
DOI - 10.33549/physiolres.931801
Subject(s) - fgf21 , medicine , endocrinology , fgf19 , obesity , hormone , waist , population , fibroblast growth factor , dieting , plasma levels , weight loss , receptor , environmental health
The objective of this study was to measure plasma fibroblastgrowth factor 21 and 19 (FGF21 and FGF19) levels in patientswith Cushing's syndrome (CS) and to compare it with those oflean control subjects (C) and patients with obesity (OB).Fourteen untreated patients with CS, 19 patients with OB and 36controls were included in the study. Plasma FGF21 and FGF19levels were measured by ELISA kits, other hormonal andbiochemical parameters were measured by standard laboratorymethods. Plasma FGF19 did not significantly differ among thestudied groups. Plasma FGF21 levels were significantly higher inboth CS and OB groups relative to C group but they did not differbetween CS and OB groups. In a combined population of allthree groups FGF21 levels positively correlated with BMI, waistcircumference and percentage of total and truncal fat mass. Lessprominent inverse relationship with these parameters was foundfor FGF19. Neither FGF21 nor FGF19 were significantly related tocortisol concentrations. Increased FGF21 concentrations in bothpatients with CS and OB relative to lean subjects suggest thatexcessive body fat and/or related metabolic abnormalities ratherthan direct effects of cortisol are responsible. In contrast neitherobesity nor hypercortisolism significantly affected FGF19concentrations.